Iruplinalkib is a potent oral tyrosine kinase inhibitor belonging to the small-molecule kinase inhibitor class, developed to treat non-small cell lung cancer by targeting anaplastic lymphoma kinase and… Read more








Iruplinalkib is a potent oral tyrosine kinase inhibitor belonging to the small-molecule kinase inhibitor class, developed to treat non-small cell lung cancer by targeting anaplastic lymphoma kinase and ROS1 rearrangements. The compound functions by binding to the ATP-binding site of these receptors, effectively inhibiting the signaling pathways required for cancer cell proliferation. To support rigorous analytical testing, this category provides a comprehensive selection of Iruplinalkib reference standards, including identified process-related impurities, N-oxides, and nitroso derivatives. Pharmaceutical laboratories utilize these high-quality materials for impurity profiling, method validation, and the development of robust quality control protocols. Furthermore, stable isotope labelled compounds are available to serve as critical internal standards for accurate quantitation in complex matrices, ensuring precision in pharmacokinetic studies and ongoing stability testing of the drug substance.